Strategies for Commercialization Track Subcommittee

Julie Allickson, PhD, MS , MT(ASCP)
Wake Forest Institute for Regenerative Medicine
Winston-Salem, NC, United States

Ohad Karnieli, MBA, PhD
ATVIO Biotechnology
Tivon, Israel

Gerhard Bauer
University of California Davis
Sacramento, CA, United States

Michael Mendicino, PhD
Hybrid Concepts International
Grand Island, NY, United States

Dawn Driscoll, MBA, PhD
Isopogen Pty Ltd.
Perth, Australia

William Milligan
Steminent Biotherapeutics Inc.
Vancouver, BC, Canada

Simon Ellison, MBA – Chair
Cell and Gene Therapy Catapult
London, United Kingdom

Brian Newsom, MBA
Thermo Fisher Scientific
Knoxville, TN, United States

Miguel Forte, MD, PhD
Valbonne, France

David Williams,  OBE, FREng, DEng, PhD, CEng, FIMechE,
Loughborough University
Loughborough, United Kingdom

Quality and Operations Track Subcommittee

Shirley Bartido, PhD, MBA
Cellectis Inc.
New York, NY, United States

Day Longsomboon, MA
Interdisciplinary Stem Cell Institute
Miami, FL, United States

Rosemarie Bell, B.App.Sc, MASM – Chair
QIMR Berghofer Medical Research Institute
Brisbane, Australia

Nadim Mahmud, MD, PhD
University of Illinois Hospital and Health Sciences System
Chicago, IL, United States

Christopher Bravery, PhD
Consulting on Advanced Biologicals Ltd.
London, United Kingdom

Lynn O’Donnell, PhD
Ohio State University, James Cancer Hospital
Columbus, OH, United States

Nancy Collins, PhD
University of Toledo Medical Center
Rye, NY, United States

Karl Stasko, MPH
Dana Farber Cancer Institute
Boston, MA, United States

Rosaria Giordano, MD
Fondazione Ospedale Maggiore Policlinico
Milan, Italy

Annette Trickett, PhD, MAppSc, FIBMS
Prince of Wales Hospital
Randwick, Australia

Deborah LaMontagne,  MLS (ASCP)
Methodist University Hospital
Memphis, TN, United States

ISCT 2017

ISCT 2017